News

Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.

These aren't the most exciting businesses, but they have a lot to offer to long-term investors.

AbbVie and Pfizer chart distinct paths in revenue growth, risk, and valuation. Explore how their financials and strategies stack up for investors this year.

Pfizer (NYSE:PFE) has entered a global oncology partnership with Innovent Biologics worth up to $10.5b, focused on up to 12 early stage cancer programs, including antibody drug conjugates and multi specific antibodies. The company also reported seven year follow up results from the Phase 3 CROWN trial, indicating sustained protection from LORBRENA against disease progression and brain metastases in ALK positive advanced lung cancer. Pfizer is currently trading at $26.18, with the stock up...

Businesses with strong free cash flow tend to be more adaptable and resilient. Some of these companies shine bright by using their cash wisely to strengthen their market positions.

Pfizer could attract investors if Warsh's "regime change" at the Fed leads to market turbulence.

Summit said Harmoni-6 is the first Phase 3 study to show a "statistically significant" survival advantage over a PD-1 inhibitor plus chemotherapy.

Investing.com -- GLP-1 weight-loss and diabetes drugs may have a future role in cancer prevention and treatment, according to new research highlighted by Citi ahead of the 2026 American Society of Clinical Oncology (ASCO) meeting, adding another potential growth avenue to an already booming drug class.

Pfizer is an over-100-year-old drug company going through a rough patch, which has happened before.

Pfizer said Sunday its Braftovi-tied regimen nearly doubled the length of time colon cancer patients lived without getting sicker.

Lawmakers and some investors are warning about the growing reliance of US pharmaceutical companies on China, raising the prospect of national...

Due to Pfizer’s underperformance relative to its peers over the past year, Wall Street analysts remain cautious about the stock’s prospects

Pfizer Inc. and China’s Innovent Biologics have announced a global licensing and collaboration agreement. The deal, valued at up to $10.5 billion, is set to develop 12 early-stage cancer drugs. The agreement comprises an upfront payment of $650 million to...

Often, investors and Wall Street analysts focus on the short term and don't give enough thought to the long term.

Pfizer and Innovent strike a global cancer-drug partnership as Chinese biotech licensing momentum accelerates.

Pfizer and Innovent signed a global oncology deal worth up to $10.5 billion.

LLY's $4B vaccine push is boosting interest in healthcare ETFs like IHE with heavy exposure to the drugmaker.

The U.S. pharma giant will pay $650 million upfront to China's Innovent Biologics to co-develop 12 early-stage oncology programs

Innovent Biologics will receive $650m upfront and could earn up to $9.85bn in additional milestone payments.

With AI now capable of analyzing decades’ worth of data, FDA is pushing pharma to leverage its “enormous, uptapped value” by repurposing drugs

Involving up to 12 antibody drugs, the alliance is the latest broad partnership between Chinese biotech and a multinational pharmaceutical company.

Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some may still have unproven business models, leaving them vulnerable to the ebbs and flows of the broader market.

The smart money on Pfizer (NYSE: PFE) is sending a quieter signal than the financial press typically rewards: institutional analysts are constructive, insiders are not transacting in size in either direction, and the dividend yield is doing the heavy lifting. With shares at $26.21 and a Wall Street consensus target of $29.19, the absence of ... Insiders Aren’t Buying Pfizer Stock at $26 and That’s Actually a Good Thing

Eli Lilly (LLY) stock has surged to new record highs of over $1,000 a share, cementing its position as one of the market's most dominant growth stories and the first pharmaceutical firm worth $1 trillion.

ABBV's oncology revenues dip 3% in Q1 as Imbruvica sales slide, though Venclexta, Elahere and Epkinly post solid gains.

BioNTech’s future rests entirely on the success of its pipeline, now that its pandemic-era glory days are firmly in the rearview mirror. Wall Street is betting the company’s next act in oncology will be worth the wait. UBS analyst David Dai moved off the sidelines Wednesday as he upgraded BioNTech stock to Buy from Neutral with a $135 price target, up from $117.

PFE is banking on new launches, Seagen assets and pipeline progress to counter a looming patent cliff through 2030.

Pfizer Inc. (NYSE:PFE) ranks among the best retirement stocks to buy now. On May 5, BofA Securities boosted its price objective for Pfizer Inc. (NYSE:PFE) to $27 from $26, retaining a Neutral rating on the company shares. Following Pfizer’s first-quarter performance, the firm raised its fiscal 2026 revenue and earnings per share forecasts. The pharmaceutical […]

These three dividend stocks combine strong yields with resilient businesses.

With $14.2bn in projected revenue losses over six years, the Eliquis loss-of-exclusivity event is set to become one of the most consequential patent cliffs in pharmaceutical history — and a stark illustration of how quickly generic entry can dismantle even the industry's most entrenched brands.